Catamaran Bio General Information Description.

Catamaran bio funding. Catamaran Bio Inc a biotechnology company developing allogeneic CAR-NK cell therapies to treat cancer today announced that the company has launched with 42 million in financingSofinnova. Sofinnova Partners and Lightstone Ventures co-led the Series A round that is part of the launch financing with participation by founding investor SV Health Investors as well as Takeda Ventures and Astellas Venture Management. The leadership team at Catamaran Bio has deep expertise in cell therapy research and product development and the team includes.

Catamaran Bio a biotechnology company developing allogeneic CAR-NK cell therapies to treat cancer has launched with 42 million in financing. The company engages in using genetic engineering of natural killer cells to target a number of therapeutic areas with high unmet needs enabling medical practitioners and individuals to procure therapies for treating their conditions. A new company is underway creating off-the-shelf engineered cells from the immune system as cancer treatments and raising 42 million in venture funds.

This round is a part of their launch financing. Catamaran Bio Inc in Cambridge Massachusetts is spun-off from medical school research labs at University of Minnesota and George Washington. Celeste joined Catamaran as Senior Vice President Research in June 2020.

April 26 2021 Catamaran Bio Inc a biotechnology company developing allogeneic CAR-NK cell therapies to treat patients with significant unmet medical need today announced the appointment of Scott Holmes MS MBA as Chief Financial OfficerMr. She brings more than 16 years of experience in research and drug discovery in biotech and large pharma. Vipin Suri PhD MBA Chief Scientific Officer who has more than 20 years of biopharmaceutical experience including as a co-founder of Obsidian Therapeutics and Serien formerly Raze Therapeutics and earlier in R.

Was acquired by OptumRx for 128B on Mar 30 2015. Catamaran Bio has 26 employees at their 1 location and 42 m in total funding. Prior to Catamaran Celeste served as Vice President of Cell Therapy at Obsidian Therapeutics where she led.

See insights on Catamaran Bio including office locations competitors revenue financials executives subsidiaries and more at Craft. November 23 2020 Catamaran Bio a Cambridge Mass-based developer of developing allogeneic CAR-NK cell therapies to treat cancer raised 42 million in Series A fundingSofinnova Partners and Lightstone Ventures co-led and were joined by Takeda Ventures Astellas Venture Management and founding backer SV Health Investors. Catamaran Bio founded by life sciences investors and academic research groups including the UMN Technology Commercializations Venture Center has raised a whopping 42 million total through its seed and Series A funding rounds providing crucial support for the company to retain top talent and accelerate the development of its cancer therapies.